Literature DB >> 31038758

Muscle Alterations Are Associated With Minimal and Overt Hepatic Encephalopathy in Patients With Liver Cirrhosis.

Silvia Nardelli1, Barbara Lattanzi1, Manuela Merli1, Alessio Farcomeni2, Stefania Gioia1, Lorenzo Ridola1, Oliviero Riggio1.   

Abstract

Muscle alterations (myosteatosis and sarcopenia) are frequent in cirrhosis and related to some complications including overt hepatic encephalopathy (HE). The aim of our study was to investigate the relationship between muscle alterations and minimal HE (MHE) and their role in the risk of overt HE. Sixty-four patients with cirrhosis were administered the Psychometric Hepatic Encephalopathy Score and animal naming test to detect MHE. Computed tomography was used to analyze the skeletal muscle index and attenuation. The incidence of the first episode of HE, taking into account the competing risk nature of the data, was estimated. Myosteatosis was observed in 24 patients (37.5%), sarcopenia in 37 (58%), and MHE in 32 (50%). Both myosteatosis (62.5% versus 12.5%, P < 0.001) and sarcopenia (84% versus 31%, P < 0.001) were more frequent in patients with MHE. The variables independently associated with the presence of MHE were sarcopenia, previous overt HE, and myosteatosis. Thirty-one (48%) patients developed overt HE over 16.1 ± 13 months; myosteatosis was detected in 68% and sarcopenia in 84% of them. Sarcopenia and myosteatosis were also independently associated with the development of overt HE. Venous ammonia was significantly higher in patients with sarcopenia (62.6 ± 17.7 versus 41.4 ± 16.1 μg/dL, P < 0.001) and in patients with myosteatosis (65.2 ± 19.2 versus 46.7 ± 17.1 μg/dL, P < 0.001) and inversely correlated to both parameters. Survival was significantly lower in malnourished patients compared to patients without myosteatosis or sarcopenia (P < 0.001).
Conclusion: Myosteatosis and sarcopenia, probably by reducing the handling of ammonia in the muscle, are independently associated with MHE and the risk of overt HE in patients with cirrhosis; in malnourished patients, the amelioration of nutritional status may be a goal to decrease both the prevalence of MHE and the incidence of overt HE.
© 2019 by the American Association for the Study of Liver Diseases.

Entities:  

Year:  2019        PMID: 31038758     DOI: 10.1002/hep.30692

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  28 in total

1.  The prognosis and incidence of hepatic encephalopathy of patients with liver cirrhosis treated with proton pump inhibitors: A multicenter retrospective study in Japan.

Authors:  Akira Sakamaki; Kenya Kamimura; Takeshi Yokoo; Akihiko Osaki; Seiichi Yoshikawa; Yoshihisa Arao; Toru Setsu; Hiroteru Kamimura; Nobuo Waguri; Manabu Takeuchi; Kazuhiro Funakoshi; Shuji Terai
Journal:  Medicine (Baltimore)       Date:  2021-08-13       Impact factor: 1.817

Review 2.  Hepatic encephalopathy.

Authors:  Dieter Häussinger; Radha K Dhiman; Vicente Felipo; Boris Görg; Rajiv Jalan; Gerald Kircheis; Manuela Merli; Sara Montagnese; Manuel Romero-Gomez; Alfons Schnitzler; Simon D Taylor-Robinson; Hendrik Vilstrup
Journal:  Nat Rev Dis Primers       Date:  2022-06-23       Impact factor: 65.038

Review 3.  Changing Epidemiology of Cirrhosis and Hepatic Encephalopathy.

Authors:  Jeremy Louissaint; Sasha Deutsch-Link; Elliot B Tapper
Journal:  Clin Gastroenterol Hepatol       Date:  2022-08       Impact factor: 13.576

Review 4.  Diabetes mellitus - risk factor and potential future target for hepatic encephalopathy in patients with liver cirrhosis?

Authors:  Simon Johannes Gairing; Eva Maria Schleicher; Christian Labenz
Journal:  Metab Brain Dis       Date:  2022-08-24       Impact factor: 3.655

5.  The improvement in body composition including subcutaneous and visceral fat reduces ammonia and hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.

Authors:  Stefania Gioia; Lorenzo Ridola; Ludovica Cristofaro; Manuela Merli; Jessica Faccioli; Oliviero Riggio; Silvia Nardelli
Journal:  Liver Int       Date:  2021-09-28       Impact factor: 8.754

6.  Determinants of prognosis in cirrhosis: a new outlook.

Authors:  Lorenzo Ridola; Stefania Gioia; Jessica Faccioli; Silvia Nardelli; Oliviero Riggio
Journal:  Hepatobiliary Surg Nutr       Date:  2022-10       Impact factor: 8.265

Review 7.  Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications.

Authors:  Csaba Matyas; György Haskó; Lucas Liaudet; Eszter Trojnar; Pal Pacher
Journal:  Nat Rev Cardiol       Date:  2020-09-30       Impact factor: 32.419

8.  What diet should I recommend my patient with Hepatic Encephalopathy?

Authors:  Jawaid Shaw; Victoria Tate; Jennifer Hanson; Jasmohan S Bajaj
Journal:  Curr Hepatol Rep       Date:  2020-03-05

9.  Prediction of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt treatment: a cohort study.

Authors:  Yang Yang; Sirui Fu; Bin Cao; Kenan Hao; Yong Li; Jianwen Huang; Wenfeng Shi; Chongyang Duan; Xiao Bai; Kai Tang; Shirui Yang; Xiaofeng He; Ligong Lu
Journal:  Hepatol Int       Date:  2021-05-11       Impact factor: 6.047

Review 10.  Current approach to treatment of minimal hepatic encephalopathy in patients with liver cirrhosis.

Authors:  Segundo Moran; Marlene López-Sánchez; María Del Pilar Milke-García; Gustavo Rodríguez-Leal
Journal:  World J Gastroenterol       Date:  2021-06-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.